- Tempus AI, Inc. (TEM, Financial) integrates its AI clinical assistant, Tempus One, into EHR systems, enhancing oncology treatment support.
- The platform now incorporates ASCO's guidelines and offers real-time clinical workflow assistance.
- Tempus expands its Agent Builder tool, collaborating with partners to develop customized AI solutions.
Tempus AI, Inc. (TEM), a leader in AI-driven precision medicine, has announced significant advancements in its AI clinical assistant, Tempus One, by integrating it directly into electronic health record (EHR) systems. This integration aims to enhance treatment decision-making for physicians, particularly in oncology, by providing real-time, AI-driven insights.
Tempus One, now equipped with American Society of Clinical Oncology (ASCO) guidelines, empowers oncologists with access to evidence-based treatment and care recommendations, facilitating personalized patient care. The platform streamlines clinical workflows by offering features such as pre-appointment preparation, real-time in-appointment support, and post-appointment assistance.
The updated version of Tempus One also introduces an Agent Builder tool, which allows select partner providers to develop custom AI agents. These agents help streamline administrative processes such as generating patient overviews and transcribing patient conversations to be included in EHR records.
Ryan Fukushima, Chief Operating Officer of Tempus, highlighted the importance of these innovations in addressing the challenges faced by healthcare professionals, emphasizing the potential of AI to connect disparate systems and deliver actionable insights efficiently.
Tempus continues its mission to advance precision medicine, leveraging a vast library of multimodal data to support clinicians in delivering personalized patient care and developing optimal therapeutic solutions.
